NCT00741793

Biologic Treatment Registry Across Canada

BioTRAC (BIOLOGIC TREATMENT REGISTRY ACROSS CANADA)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 2,821 (actual)
• Sponsor: Janssen Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This registry is a multi-center, prospective, longitudinal, observational program that will gather and analyse data on participants treated with infliximab, golimumab, golimumab Intravenous (I.V) or ustekinumab. Treatment will be prescribed by the physician according to actual clinical practice or standard of care for Rheumatoid Arthritis (RA), Axial Spondyloarthritis (AxSpA) , Psoriatic Arthritis (PsA); there will be no randomized assignments to treatment. At baseline and approximately every 6 months thereafter, information will be collected to assess safety, clinical outcomes, quality of life, comorbidities, pharmacoeconomics and treatment regimens among cohorts of participants receiving infliximab, golimumab, golimumab I.V or ustekinumab for the treatment of RA, AxSpA and PsA.

Detailed description

Participants will be selected for this registry using a non-probability sampling method.

Conditions

• Arthritis, Rheumatoid
• Spondyloarthritis, Axial
• Arthritis, Psoriatic

Timeline

• Start date: 2002-02-12
• Primary completion: 2018-06-27
• Completion: 2018-06-29
• First posted: 2008-08-26
• Last updated: 2025-04-27

Locations

1 site across 1 country: Canada